0.25Open0.25Pre Close0 Volume20 Open Interest2.50Strike Price0.00Turnover192.85%IV37.50%PremiumSep 20, 2024Expiry Date0.00Intrinsic Value100Multiplier26DDays to Expiry0.25Extrinsic Value100Contract SizeAmericanOptions Type0.4326Delta0.3823Gamma8.00Leverage Ratio-0.0079Theta0.0004Rho3.46Eff Leverage0.0021Vega
Trinity Biotech Stock Discussion
and Raises Guidance For 2024 TrinScreen HIV Sales
DUBLIN, Ireland (May 13, 2024)…. Trinity Biotech plc (Nasdaq: TRIB) a commercial stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced that it has received substantial additional orders for TrinScreen HIV, bringing total orders received to date for supply in 2024 to ap...
Benzinga· 4 mins ago
Moomoo 24/7· 2 mins ago
The company said this outlook is predicated solely on growth from the existing businesses including haemoglobin testing and HIV, and planned improvements to operating margins, with no contribution from the recently acquired biosensor business.
No comment yet